{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:01:07Z","timestamp":1791838867958,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Neuroendocrinology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lutetium peptide receptor radio nuclide therapy (Lu\u2010PRRT) is an effective treatment for progressive, metastatic, somatostatin\u2010receptor\u2010positive, well\u2010differentiated neuroendocrine tumours (WD\u2010NETs). Here, we report a single centre experience of real\u2010world efficacy, long\u2010term side effects, and challenges of this treatment. This was a retrospective analysis. All patients linked with our centre who had Lu\u2010PRRT were included. Clinicopathological data were analysed using descriptive statistics, Kaplan\u2013Meier, and Cox regression. A total of 45 patients had Lu\u2010PRRT, of those 30 (67%) were males, and 13 (29%) were more than 65\u2009years old. The primary site was small intestine in 30 (67%) patients, pancreas in seven (16%) patients, and lung in three (7%) patients. The tumor was grade 1 in 15 (35%) patients, grade 2 in 22 (48%) patients, and grade 3 in six (13%) patients. A total of 41 (91%) patients had liver metastasis, and 20 (44%) patients had carcinoid syndrome. Lu\u2010PRRT was the second\u2010line therapy in all patients. Krenning's score was 4 in 36 (80%) patients and 3 in nine (20%) patients. The median waiting time to start Lu\u2010PRRT therapy was 87\u2009days. The median follow\u2010up was 41\u2009months. A total of 23 (51%) patients had a partial response, 18 (40%) patients had stable disease, and four (9%) patients had progression. None of the patients had a complete response. The median progression\u2010free survival (PFS) was 38\u2009months (95% CI: 25.8\u201350.1). The median overall survival (OS) was not reached. Nine patients died during follow\u2010up (death from any cause). Prior treatment with targeted therapies or high dose somatostatin analogues were negative predictors of Lu\u2010PRRT outcome (\n                    <jats:italic>p<\/jats:italic>\n                    \u2010values of &lt; .001 and &lt; .045, respectively). There were two serious haematological toxicities, one patient developed acute myeloid leukaemia (AML), and the other developed chronic myeloid leukaemia (CML). Lu\u2010PRRT is an effective second\u2010line treatment for metastatic WD\u2010NETs. The effect of targeted therapies on Lu\u2010PRRT outcome was significant and needs to be clarified in further studies.\n                  <\/jats:p>","DOI":"10.1111\/jne.13138","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:43:20Z","timestamp":1649767400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["<scp>Real\u2010world<\/scp>\n                    efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-0736","authenticated-orcid":false,"given":"Hussein","family":"Almeamar","sequence":"first","affiliation":[{"name":"National Centre for Neuroendocrine Tumours, ENETS Centre of Excellence St. Vincent's University Hospital  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cullen","sequence":"additional","affiliation":[{"name":"National Centre for Neuroendocrine Tumours, ENETS Centre of Excellence St. Vincent's University Hospital  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-672X","authenticated-orcid":false,"given":"David J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Radiology St. Vincent's University Hospital  Dublin Ireland"},{"name":"UCD School of Medicine  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[{"name":"National Centre for Neuroendocrine Tumours, ENETS Centre of Excellence St. Vincent's University Hospital  Dublin Ireland"},{"name":"UCD School of Medicine  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"ENETS Centre of Excellence Royal Free Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Welin","sequence":"additional","affiliation":[{"name":"Department of Endocrine Oncology, ENETS Centre of Excellence Uppsala University Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"O'Shea","sequence":"additional","affiliation":[{"name":"National Centre for Neuroendocrine Tumours, ENETS Centre of Excellence St. Vincent's University Hospital  Dublin Ireland"},{"name":"UCD School of Medicine  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"O'Toole","sequence":"additional","affiliation":[{"name":"National Centre for Neuroendocrine Tumours, ENETS Centre of Excellence St. Vincent's University Hospital  Dublin Ireland"},{"name":"Department of Clinical Medicine Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903183401107"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000457957"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2000\u20100001"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749\u20106632.1994.tb17300.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010011\u20101902\u20101"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010011\u20102039\u2010y"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475526"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.125336"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.01.009"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.WJNM_25_17"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010018\u20103967\u20106"},{"issue":"2","key":"e_1_2_10_17_1","first-page":"S219","article-title":"Scintigraphy and radionuclide therapy with [indium\u2010111\u2010labelled\u2010diethyl triamine penta\u2010acetic acid\u2010D\u2010Phe1]\u2010octreotide","volume":"31","author":"Krenning EP","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4784"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010018\u20104158\u20101"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010017\u20103821\u20102"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC\u201018\u20100424"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070909"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010018\u20103945\u2010z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2012.09.007"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201011\u20102089"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2015.1876"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40336\u2010019\u201000342\u20103"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010019\u201004389\u20102"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1282"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975"}],"container-title":["Journal of Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jne.13138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jne.13138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jne.13138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:35:25Z","timestamp":1692750925000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jne.13138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/jne.13138"],"URL":"https:\/\/doi.org\/10.1111\/jne.13138","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/JNE.13138\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13138\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13138\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13138\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13138\/v2\/response1","asserted-by":"object"}]},"ISSN":["0953-8194","1365-2826"],"issn-type":[{"value":"0953-8194","type":"print"},{"value":"1365-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"2021-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13138"}}